Sangamo BioSciences Stock News

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript

Sangamo Therapeutics press release (SGMO): Q4 GAAP EPS of -$0.26 beats by $0.09.Revenue of $28M (+8.5% Y/Y) beats by $0.64M.Cash, cash equivalents and marketable securities as…

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to advance the development of genomic medicines for patients across multiple therapeutic areas using our innovative technologies,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We along with our partners presented compelling clinical data in our three lead pro

Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to announce Q4 earnings results on Thursday, Feb. 24, after market close.Consensus EPS estimate is -$0.34

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price on Thursday, February 10, fall -2.17% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.86. A look at the stock’s price movement, the close in the last trading session was $5.99, moving within a range at $5.755 and $6.27. The beta value … After Sangamo Therapeutics Inc. (NASDAQ:SGMO) Fell -2.17% What Analysts Have Been Expecting Read More »

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price closed higher on Monday, February 07, jumping 2.88% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Sangamo Therapeutics (SGMO) said preliminary data from a phase 1/2 study, dubbed STAAR, of its gene therapy isaralgagene civaparvovec (ST-920) continued to be well tolerated in…

Sangamo Therapeutics Inc (NASDAQ: SGMO ) announced updated preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), Fabry disease gene therapy candidate. Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide (Gb3), in the body''s cells. It is caused by mutations in the galactosidase alpha gene ( GLA ), resulting in deficient alpha-galactosidase A (α-Gal A) enzyme activity, necessary for metabolizing … Full story available on Benzinga.com

Sangamo Therapeutics Inc SGMO announced updated preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), Fabry disease gene therapy candidate. Get the Inside Access

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the November 9, 2021 cutoff date, the investigational treatment continued to be well tolerated and that the four longest treated patients conti